No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NKTR240517C1500
- 0.20
- +0.05+33.33%
15min DelayClose May 8 15:58 ET
0.25High0.20Low
0.25Open0.15Pre Close7 Volume609 Open Interest1.50Strike Price145.00Turnover118.34%IV3.66%PremiumMay 17, 2024Expiry Date0.14Intrinsic Value100Multiplier8DDays to Expiry0.06Time Value100Contract SizeAmericanOptions Type0.7197Delta1.1111Gamma8.20Leverage Ratio-0.0060Theta0.0002Rho5.90Eff Leverage0.0009Vega
Intraday
- 5D
- 1D
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersClover Health Investments (NASDAQ:CLOV) shares increased by 14.9% to $0.85 during Tuesday's after-market session. The market value of their outstanding shares is at $421.4 million. The company'
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fin
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shar
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Express News | Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
Express News | Nektar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 8.4% at $1.53
Comments
$Nektar Therapeutics(NKTR.US$ raise ur hand if u bought this above 50dollars 😂😂😂
$Nektar Therapeutics(NKTR.US$ Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
1
$Nektar Therapeutics(NKTR.US$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
1
Nektar Therapeutics' CEO, Howard Robin, is pleased with the deal, stating it strengthens the company's finances and extends its cash runway to Q3 2026. He also emphasized the potential of rezpegaldesleukin, a novel biologic in Phase 2b studies.
Read more